Medical/Pharmaceuticals
The 2nd International Cerebro-cardiovascular Medical Innovation Summit (ICMIS 2025) Opens in Hong Kong: AI Technology and Digital Health Usher in a New Chapter of Translational Medicine.
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Cerebro-cardiovascular conditions have continued to pose a public health burden. The convergence of population ageing and lifestyle risk factors has made "earlier detection, earlier intervention, and accessible and affordable prevention and management" a c...
2025-12-11 19:19
2361
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
* Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance * The study a...
2025-12-11 14:12
2623
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
* Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases * OTR Therapeut...
2025-12-11 14:00
1852
Rhinocare Korea Accelerates Global Expansion with Singapore Joint Venture
K-Healthtech Firm Targets Rapid Global Scale-Up with Drug-Free Nasal-Care Innovation SINGAPORE and SEOUL, South Korea, Dec. 11, 2025 /PRNewswire/ -- Rhinocare Korea, a medtech innovator specializing in drug-free respiratory care, announced plans to establish a joint venture (JV) inSingapore as p...
2025-12-11 12:46
3454
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment...
2025-12-11 09:53
2587
Hakka Medicine: From Millennia of Heritage to Modern Industrialization - A Health Path Connecting the World
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southernChina, carrying profound historical heritage and unique clinical value.The Seventh World Hakka Entrepreneurs Conven...
2025-12-11 08:00
1721
Samsung Biologics recognized as a global leader in water security
* Company receives the highest Water Security rating in two years into participation * Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 10, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing or...
2025-12-11 07:30
2833
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinica...
2025-12-11 03:30
2184
DNV RECEIVES CMS APPROVAL FOR NEW AMBULATORY SURGERY CENTERS ACCREDITATION PROGRAM
New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory...
2025-12-10 22:32
3454
DNV LAUNCHES ACCREDITATION FOR AMBULATORY SURGERY CENTERS
New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory...
2025-12-10 22:16
3344
Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk
Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals")
and Formation Bio
2025-12-10 22:05
4427
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters Reinvigoration of immune system + turning cold tumors hot Preliminary ex-vivo data in HER2+ patients demonstrates immune reinvigoration and reductions...
2025-12-10 21:00
5953
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
Two leading entities in cancer research pledge scientific collaboration to advance precision oncology. HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025 /PRNewswire/ -- Indivumed is excited to announce its partnership with the world-renowned Wilmot Cancer Institute at theUniversity of Rocheste...
2025-12-10 21:00
2650
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. HONG KONG, Dec. 10, 2025 ...
2025-12-10 17:15
3254
Berlin Heals Welcomes Rob ten Hoedt as New Chairman of the Board
ZUG, Switzerland, Dec. 10, 2025 /PRNewswire/ -- Berlin Heals Holding AG (Zug, Switzerland) is pleased to announce the appointment of Rob ten Hoedt as the new Chairman of the Board of Directors. "We are thrilled to welcome someone of Rob ten Hoedt's caliber to the Board," saidMarko Bagaric, Co-fo...
2025-12-10 17:00
1280
Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day inShanghai. The event focused on the latest advancements in the field of antibody-drug c...
2025-12-10 14:20
2341
DKSH Healthcare Launches Three-Part Whitepaper Series Showcasing Asia Pacific's Growing Healthcare Outsourcing Opportunity
DKSH Business Unit Healthcare Launches a three-part whitepaper series to help healthcare and life science companies explore industry trends and current market pressures to re-think commercial go-to market approaches in theAsia Pacific region. The whitepaper series demonstrates how strategic Comme...
2025-12-10 14:00
1793
Beijing 101 Launches Tri-Action Scalp Revival Treatment, The Ultimate Multi-Technology Scalp Rejuvenation Solution
SINGAPORE, Dec. 10, 2025 /PRNewswire/ -- Beijing 101 Hair Consultants is thrilled to announce the launch of its latest treatment innovation – the Tri-Action Scalp Revival Treatment – a systematic, multi-technology hair and scalp treatment that cleanses, nourishes, and rejuvenates the scalp throug...
2025-12-10 10:00
1511
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a$108 million Series B financing round. The funding round was backed by a distinguished group ...
2025-12-10 09:30
2728
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2025-12-10 08:26
2149
Week's Top Stories
Most Reposted
MTR Lab and ZGC Science City Ltd Establish Ecosystem Partnership
[Picked up by 310 media titles]
2026-03-18 12:00
Nature's Capital: Why Asia's Governments Are Turning to Nature-Based Solutions
[Picked up by 301 media titles]
2026-03-17 08:00Beijing InfoComm China 2026 Conference Lineup Presents Future of AI in Tech Aligning with the Nation's Next Strategic Five-Year Plan
[Picked up by 296 media titles]
2026-03-18 08:00
Agoda and Gangwon State Join Hands to Elevate Gangwon into a Premier Global Travel Destination
[Picked up by 293 media titles]
2026-03-17 11:29
Most Read
HTCO Launches U.S. Strategic Initiative Led by Chairman Christopher Nixon Cox, Establishes Independent Governance Committee for U.S. Operations
2026-03-13 21:30
7504
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
2026-03-13 21:59
7040
